← Back to patent-cliff list
Subasumstat
Tier C — Watch / tradeSubasumstat
Takeda Pharmaceutical Company Limited
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SAE1
Indications (approved)：Solid tumour, Non-Hodgkin lymphoma, Head and neck cancer, Lymphoma, Haematological malignancy, Multiple myeloma, Cervical cancer
Regional status
US
Phase II
2018-10-01
EU
Phase II
2018-10-22
China
Phase II
2019-10-15
Japan
Phase II
2019-10-15
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Subasumstat?
Approved indications include: Solid tumour, Non-Hodgkin lymphoma, Head and neck cancer, Lymphoma, Haematological malignancy, Multiple myeloma, Cervical cancer.
When does the Subasumstat patent expire?
No public expiry year is available for Subasumstat yet; this page updates once verified.
How do I get a quote for Subasumstat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08